Innoviva (INVA) Price & Analysis

Compare

329 Followers

INVA Stock Chart & Stats

$20.62

-$0.05(-0.29%)

At close: Jan 08 4:00 PM EST

$20.62

-$0.05(-0.29%)

Day’s Range― - ―

52-Week Range$16.52 - $22.76

Previous CloseN/A

Volume64.08K

Average Volume (3M)837.41K

Market Cap

$1.55B

Enterprise Value$1.28B

Total Cash (Recent Filing)$533.10M

Total Debt (Recent Filing)$323.23M

Price to Earnings (P/E)14.8

Beta0.19

Next Earnings

Mar 04, 2026

EPS Estimate

0.6

Last Dividend Ex-Date

Sep 08, 2015

Dividend YieldN/A

Share Statistics

EPS (TTM)1.08

Shares Outstanding74,769,060

10 Day Avg. Volume670,137

30 Day Avg. Volume837,406

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)1.57

Price to Sales (P/S)3.03

P/FCF Ratio5.78

Enterprise Value/Market Cap0.82

Enterprise Value/Revenue3.29

Enterprise Value/Gross Profit3.80

Enterprise Value/Ebitda6.36

Forecast

1Y Price Target

$32.00

Price Target Upside55.19% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthInnoviva ended the period with $476.5 million in cash and cash equivalents, demonstrating its balance sheet strength.

Financial PerformanceInnoviva's financial results revealed solid operational execution and royalty-based revenue resilience, with multiple revenue streams exceeding expectations.

Product Growth ExpectationsThere are moderately higher growth expectations for several of Innoviva's proprietary marketed products, sold via the company's Innoviva Specialty Therapeutics platform.

Bears Say

Commercial Environment ChallengesThe underlying products for the GSK royalties face LOE and IRA pressures, shifting the focus to the IST business to drive growth in a challenging commercial environment.

Growth ExpectationsThe bar for performance needed from the IST platform is now raised, indicating higher expectations for future growth.

Patent Expiration ConcernsThe company's 2031 royalty-related patent cliff is anticipated to start weighing on stock performance, reflecting historical trends in the pharma sector.

Innoviva News

Roth Capital healthcare analyst holds an analyst/industry conference call

Healthcare Analyst Pachaiyappan, along with Dr. Wexner, System Chief for Colorectal Surgery, Georgetown University Hospital, the science and...

6d ago

BDX

JNJ

Innoviva Reports Strong Q3 2025 Financial Results

Innoviva ( ($INVA) ) has released its Q3 earnings. Here is a breakdown of the information Innoviva presented...

30d ago

INVA

Innoviva management to meet virtually with Oppenheimer

Virtual Meeting to be held on November 12-13 hosted by Oppenheimer. Published first on TheFly – the ultimate...

1M ago

INVA

Innoviva’s Strong Q3 2025 Performance and Growth Prospects Drive Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Innoviva today and set a price target of...

1M ago

INVA

Innoviva reports Q3 EPS $1.08 vs. 2c last year

Reports Q3 revenue $107.8M, consensus $91.3M. “Innoviva (INVA) delivered strong third-quarter performance across each area of our business....

1M ago

INVA

Innoviva board authorizes $125M share repurchase program

Innoviva’s (INVA) Board of Directors has authorized a new share repurchase program under which the Company may repurchase...

1M ago

INVA

Innoviva (INVA) Q3 Earnings Cheat Sheet

Innoviva (INVA) is scheduled to report 3rd quarter earnings on 10/29/2025. Regarding Q3 estimates, Wall Street analysts expect...

2M ago

INVA

Innoviva’s Future Challenges: Sell Rating Amid Patent Cliff and Revenue Pressures

Innoviva (INVA) has received a new Sell rating, initiated by Goldman Sachs analyst, Asad Haider. Asad Haider has...

2M ago

INVA

Innoviva initiated with a Sell at Goldman Sachs

Goldman Sachs initiated coverage of Innoviva (INVA) with a Sell rating and $17 price target The stock’s recent...

2M ago

INVA

Arm initiated, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4M ago

ARM

Innoviva initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Innoviva (INVA) with an Outperform rating and $35 price target Innoviva is a holding...

4M ago

INVA

Innoviva price target raised to $45 from $40 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Innoviva (INVA) to $45 from $40 and...

4M ago

INVA

Innoviva Reports Strong Q2 2025 Financial Results

Innoviva ( ($INVA) ) has released its Q2 earnings. Here is a breakdown of the information Innoviva presented...

4M ago

INVA

Innoviva reports Q2 EPS 77c vs. (55c) last year

Reports Q2 revenue $100.3M vs. $99.9M last year. “Innoviva (INVA) continued to deliver impressive financial and operational results...

4M ago

INVA

INVA FAQ

What was Innoviva Inc’s price range in the past 12 months?

Innoviva Inc lowest stock price was $16.52 and its highest was $22.76 in the past 12 months.

What is Innoviva Inc’s market cap?

Innoviva Inc’s market cap is $1.55B.

When is Innoviva Inc’s upcoming earnings report date?

Innoviva Inc’s upcoming earnings report date is Mar 04, 2026 which is in 83 days.

How were Innoviva Inc’s earnings last quarter?

Innoviva Inc released its earnings results on Nov 05, 2025. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.62.

Is Innoviva Inc overvalued?

According to Wall Street analysts Innoviva Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Innoviva Inc pay dividends?

Innoviva Inc pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here

What is Innoviva Inc’s EPS estimate?

Innoviva Inc’s EPS estimate is 0.6.

How many shares outstanding does Innoviva Inc have?

Innoviva Inc has 74,769,060 shares outstanding.

What happened to Innoviva Inc’s price movement after its last earnings report?

Innoviva Inc reported an EPS of $1.08 in its last earnings report, beating expectations of $0.46. Following the earnings report the stock price went up 12.891%.

Which hedge fund is a major shareholder of Innoviva Inc?

Currently, no hedge funds are holding shares in INVA

Innoviva Stock Smart Score

Neutral

Fundamentals

Return on Equity

15.17%

Trailing 12-Months

Asset Growth

16.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innoviva Inc

Innoviva, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for chronic respiratory diseases. The company operates primarily in the healthcare sector, specializing in the discovery and commercialization of medicines that target serious diseases, with a particular emphasis on conditions such as asthma and chronic obstructive pulmonary disease (COPD). Innoviva's core products include inhalation therapies and treatments that leverage advanced delivery technologies to enhance patient outcomes and compliance.

Innoviva (INVA) Earnings & Revenues

Historic Earnings Reports

INVA Stock 12 Month Forecast

Average Price Target

$32.00

▲(55.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","22":"$22","30":"$30","38":"$38","46":"$46"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,22,30,38,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,20.26153846153846,22.323076923076922,24.384615384615387,26.446153846153848,28.50769230769231,30.56923076923077,32.63076923076923,34.69230769230769,36.753846153846155,38.815384615384616,40.87692307692308,42.93846153846154,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,19.26153846153846,20.323076923076922,21.384615384615383,22.446153846153845,23.507692307692306,24.56923076923077,25.630769230769232,26.692307692307693,27.753846153846155,28.815384615384616,29.876923076923077,30.93846153846154,{"y":32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.2,18.107692307692307,18.015384615384615,17.923076923076923,17.83076923076923,17.73846153846154,17.646153846153847,17.553846153846152,17.46153846153846,17.369230769230768,17.276923076923076,17.184615384615384,17.092307692307692,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.12,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.35,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >